Evidences on muscular relaxants for outpatient use: A review of the literature
DOI:
https://doi.org/10.5712/rbmfc12(39)1500Keywords:
Neuromuscular Agents. Evaluation of Results of Therapeutic Interventions. Ambulatory Care. Drugs for Primary Health Care. ReviewAbstract
Objective: To evaluate the evidence on the efficacy and adverse effects of oral muscle relaxants available in Brazil for spasticity, musculoskeletal conditions, fibromyalgia and tension headache. Methods: A literature review assessment was carried out based on systematic reviews published in the Medline, Virtual Health Library (VHL), Cochrane Library and National Institute for Health and Care Excellence (NICE) up to December 2016, that evaluated the drugs considered to be muscle relaxants by Anatomical Therapeutic Chemical (ATC) and available in Brazil in oral form: cyclobenzaprine, tizanidine, carisoprodol, orphenadrine and baclofen. Results: Twenty studies were identified, 17 of which were systematic reviews and three meta-analyzes. Evidence on the efficacy of muscle relaxants consists mainly of studies with poor methodological design. Comparison studies have not shown that one skeletal muscle relaxant is superior to another. Cyclobenzaprine demonstrated efficacy in musculoskeletal conditions, such as myofascial mandibular pain, fibromyalgia and low back pain. In fibromyalgia, it has shown benefit in overall improvement and sleep. In the management of low back pain, cyclobenzaprine showed modest effect, more present in the first four days. Carisoprodol in low back pain does not appear to have difference for cyclobenzaprine but this drug may cause dependence. Baclofen and tizanidine appear to be efficacious compared to placebo and equivalent in patients with spasticity. Conclusions: Muscle relaxants in general compared to placebo or to each other showed little evidence with significant statistics. Therefore the drug selection should be based on the profile of adverse effects, patient preference, potential of abuse, potential of interaction with other drugs, cost and other characteristics of the drugs.
Downloads
Metrics
References
Pereira LCM, L’Abbate GL. Miorrelaxantes no tratamento da dor. In: Alves Neto O, Costa CMC, Siqueira JTT, Teixeira MJ, orgs. Dor: Princípios e Prática. Porto Alegre: Artmed; 2009.
Duncan BB, Schmidt MI, Giuliani ERJ. Medicina Ambulatorial: Condutas de Atenção Primária Baseadas em Evidências. 4a ed. Porto Alegre: Artmed; 2013.
Associação da Indústria Farmacêutica de pesquisa [homepage na internet]. Guia 2017 Interfarma [acesso 27 Jan 2017]. Disponível em: https://www.interfarma.org.br/guia/guia-2017/dados-do-setor#ranking-de-medicamentos
Brasil. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais 2014 [Internet]. [acesso 17 Jun 2016]. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_essenciais_rename_2014.pdf
Rebolho MCT, Rocha LE, Teixeira LR, Casarotto RA. Prevalência de dor músculo esquelética e percepção de hábitos posturais entre estudantes do ensino fundamental. Rev Med [Internet]. Jun 2011 [acesso 18 Nov 2017];90(2):68-77. Disponível em: http://www.revistas.usp.br/revistadc/article/view/58887. DOI: http://dx.doi.org/10.11606/issn.1679-9836.v90i2p68-77 DOI: https://doi.org/10.11606/issn.1679-9836.v90i2p68-77
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria Conjunta nº. 29, de maio de 2017. Anexo Protocolo Clínico e Diretrizes Terapêuticas – Espasticidade. Diario Oficial da União 30 mai 2017; Seção 1 [Internet]. [acesso 24 Jan 2018]. Disponível em: http://conitec.gov.br/images/Protocolos/Protocolo_Uso/Portaria_SAS-SCTIE_2_PCDT_Espasticidade_29_05_2017.pdf
Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014;39(6):427-35.
WHO Collaborating Centre for Drug Statistics Methodology. Updates included in the ATC/DDD [Internet]. Nydalen: WHO/Norwegian Institute of Public Health. 2016 [atualizada em 2016 dez 19; acesso 22 Dez 2016]. Disponível em: https://www.whocc.no/atc_ddd_index/?code=M03&showdescription=yes
Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária [Internet]. Consulta de Produto - Medicamentos [acesso 17 Jun 2016]. Disponível em: http://www7.anvisa.gov.br/datavisa/Consulta_Produto/consulta_medicamento.asp
Brasil. Ministério da Saúde. Secretaria de Ciência e Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de pareceres técnico-científicos/Ministério da Saúde, Secretaria de Ciência e Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia. 3ª ed., revisada e atualizada. Brasília: Ministério da Saúde; 2011. 80 p.
Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994;44(11 Suppl 9):S60-8; discussion S68-9.
Manfredini D, Landi N, Tognini F, Orlando B, Bosco M. Muscle relaxants in the treatment of myofascial face pain. A literature review. Minerva Stomatol. 2004;53(6):305-13.
Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994;44(11 Suppl 9):S53-9.
Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241-51.
Boothby LA, Doering PL, Hatton RC. Carisoprodol: a marginally effective skeletal muscle relaxant with serious abuse potential. Hosp Pharm. 2003;38(4):337-45. DOI: http://dx.doi.org/10.1177/001857870303800406 DOI: https://doi.org/10.1177/001857870303800406
Gabriel SE, Bombardier C. Clinical trials in fibrositis: a critical review and future directions. J Rheumatol Suppl. 1989;19:177-9.
Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia
with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51(1):9-13. DOI: http://dx.doi.org/10.1002/art.20076 DOI: https://doi.org/10.1002/art.20076
Roskell NS, Beard SM, Zhao Y, Le TK. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11(6):516-27. DOI: http://dx.doi.org/10.1111/j.1533-2500.2010.00441.x DOI: https://doi.org/10.1111/j.1533-2500.2010.00441.x
Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008922. DOI: https://doi.org/10.1002/14651858.CD008922.pub2
Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012(4):CD004157. DOI: http://dx.doi.org/10.1002/14651858.CD004157.pub2 DOI: https://doi.org/10.1002/14651858.CD004157.pub2
Peloso P, Gross A, Haines T, Trinh K, Goldsmith CH, Burnie S; Cervical Overview Group. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007;(3):CD000319. DOI: https://doi.org/10.1002/14651858.CD000319.pub4
Leite FM, Atallah AN, El Dib R, Grossmann E, Januzzi E, Andriolo RB, et al. Cyclobenzaprine for the treatment of myofascial pain in adults. Cochrane Database Syst Rev. 2009(3):CD006830. DOI: https://doi.org/10.1002/14651858.CD006830.pub3
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-75. DOI: http://dx.doi.org/10.1016/j.jpainsymman.2004.05.002 DOI: https://doi.org/10.1016/j.jpainsymman.2004.05.002
Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. J Spinal Disord. 2000;13(6):463-9. DOI: http://dx.doi.org/10.1097/00002517-200012000-00001 DOI: https://doi.org/10.1097/00002517-200012000-00001
Luijsterburg PA, Verhagen A, Ostelo RW, van Os TA, Peul WC, Koes BW. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J. 2007;16(7):881-99. DOI: http://dx.doi.org/10.1007/s00586-007-0367-1 DOI: https://doi.org/10.1007/s00586-007-0367-1
Browning R, Jackson JL, O’Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 2001;161(13):1613-20. DOI: http://dx.doi.org/10.1001/archinte.161.13.1613 DOI: https://doi.org/10.1001/archinte.161.13.1613
Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003(4):CD001332. DOI: https://doi.org/10.1002/14651858.CD001332
Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8(4):319-29. DOI: http://dx.doi.org/10.1191/1352458502ms795rr DOI: https://doi.org/10.1191/1352458502ms795rr
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix-x, 1-111.
Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-43. DOI: https://doi.org/10.1212/WNL.0b013e3181cbcd2f
Navarrete-Opazo AA, Gonzalez W, Nahuelhual P. Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy. Arch Phys Med Rehabil. 2016;97(4):604-18. DOI: http://dx.doi.org/10.1016/j.apmr.2015.08.417 DOI: https://doi.org/10.1016/j.apmr.2015.08.417
Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology. 2004;63(8):1357-63. Epub 2004/10/27. DOI: https://doi.org/10.1212/01.WNL.0000141863.52691.44
Taricco M, Pagliacci MC, Telaro E, Adone R. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys. 2006;42(1):5-15.
Marshall S, Teasell R, Bayona N, Lippert C, Chundamala J, Villamere J, et al. Motor impairment rehabilitation post acquired brain injury. Brain Inj. 2007;21(2):133-60. DOI: http://dx.doi.org/10.1080/02699050701201383 DOI: https://doi.org/10.1080/02699050701201383
Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database Syst Rev. 2016;10:CD010362. DOI: http://dx.doi.org/10.1002/14651858.CD010362.pub2 DOI: https://doi.org/10.1002/14651858.CD010362.pub2
Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010;32(14):2282-303. DOI: http://dx.doi.org/10.1016/j.clinthera.2011.01.005 DOI: https://doi.org/10.1016/j.clinthera.2011.01.005
See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78(3):365-70.
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.